SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting
2023-10-31
免疫疗法AACR会议ASCO会议细胞疗法
PRAGUE--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California.
Data to be presented include new preclinical results supporting the continued development of SOT201, a next-generation PD-1-inhibiting cytokine that SOTIO is progressing toward a planned first-in-human study in the second quarter of 2024. SOT201 is an antibody-cytokine fusion protein that could improve upon the efficacy of approved checkpoint inhibitors by combining PD-1 blockade with IL-15 immune stimulation in a single therapeutic construct.
Additional poster presentations at the meeting will include preclinical data on the synergistic effects of SOTIO’s IL-15 superagonist in combination with CAR T-cell therapies, as well as data on SOTIO’s IL-15 superagonist nanrilkefusp alfa.
Presentation details are as follows:
Title: “SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ and PD-1 to reinvigorate PD-1+ tumor infiltrating lymphocytes and potentiate anti-tumor efficacy”
Number: 1087
Date: November 3, 2023
Presenter: Irena Adkins, Martin Steegmaier
Title: “Combination with IL-15Rβγ superagonist, Nanrilkefusp alfa, enhances CAR T and BOXR T cell anti-tumor activity”
Number: 815
Date: November 3, 2023
Presenter: Amy Jensen-Smith
Title: “Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumor inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers”
Number: 713
Date: November 3, 2023
Presenter: Petr Danek, Lenka Palova Jelinkova
Posters will be available after presentations conclude HERE.
About SOTIO Biotech
SOTIO Biotech (SOTIO) is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The SOTIO pipeline includes SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate which entered the clinic in 2022; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumorsGPC3-expressing tumors as well as other molecules approaching clinical stage such as SOT201, our next-generation PD-1-inhibiting cytokine. SOTIO is a member of the PPF Group. For more information, please visit the company’s website at .
SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。